Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Catalyst Pharm Inc (CPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 545,544
  • Shares Outstanding, K 102,739
  • Annual Sales, $ 500 K
  • Annual Income, $ -34,000 K
  • 60-Month Beta 2.43
  • Price/Sales 1,080.81
  • Price/Cash Flow N/A
  • Price/Book 10.64

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.13
  • Number of Estimates 4
  • High Estimate -0.10
  • Low Estimate -0.20
  • Prior Year -0.06
  • Growth Rate Est. (year over year) -116.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.23 +64.40%
on 03/19/19
5.68 -6.51%
on 04/05/19
+2.23 (+72.40%)
since 03/18/19
3-Month
2.17 +144.70%
on 02/06/19
5.68 -6.51%
on 04/05/19
+2.69 (+102.67%)
since 01/18/19
52-Week
1.85 +187.03%
on 01/02/19
5.68 -6.51%
on 04/05/19
+2.76 (+108.24%)
since 04/18/18

Most Recent Stories

More News
Catalyst (CPRX) Up 58.1% Since Last Earnings Report: Can It Continue?

Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

CPRX : 5.31 (+0.95%)
Market Trends Toward New Normal in Catalyst Pharmaceuticals, Allete, Noodles, Uranium Energy, Materion, and Altisource Portfolio Solutions S.A -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Catalyst Pharmaceuticals, Inc....

UEC : 1.38 (+1.47%)
MTRN : 59.58 (-1.10%)
NDLS : 6.85 (+1.33%)
ALE : 79.53 (-0.33%)
ASPS : 23.64 (-2.80%)
CPRX : 5.31 (+0.95%)
Cancer Biology Clinical Research Seeking Answers at Cellular Level

Research for the cure for cancer has become this generation's version of President John F. Kennedy's May 25, 1961 proclamation to "Landing a man on the Moon and returning him safely". Much money and effort...

CPRX : 5.31 (+0.95%)
CCXI : 12.13 (-1.30%)
MBRX : 1.11 (+14.08%)
SEEL : 2.92 (-4.58%)
BMY : 45.52 (-0.61%)
Why 2019 U.S. Medical Device Market Is Expected to Exceed Last Year Revenues

A recent article in a medical device industry periodical, INN, said that: "2018 has been an important year for the medical device industry as M&A, technology and regulatory catalysts have impacted the...

NVRO : 65.58 (-0.17%)
MTFB : 2.12 (-3.20%)
CPRX : 5.31 (+0.95%)
PAVM : 1.17 (-3.31%)
SOLY : 11.89 (-9.99%)
Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse

Catalyst (CPRX) reports wider-than-expected loss in the fourth quarter of 2018.

CELG : 93.76 (-0.57%)
ENDP : 7.12 (-0.42%)
BDSI : 4.65 (-0.64%)
CPRX : 5.31 (+0.95%)
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular...

CPRX : 5.31 (+0.95%)
Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 19th, 2019

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular...

CPRX : 5.31 (+0.95%)
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular...

CPRX : 5.31 (+0.95%)
Catalyst Pharmaceuticals Responds to Letter from Senator Bernie Sanders

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic, neuromuscular...

CPRX : 5.31 (+0.95%)
Catalyst Pharmaceuticals Announces Publication of Clinical Data from the Investigator-Sponsored Phase IIb Study Evaluating Firdapse(R) for the Treatment of MuSK Antibody Positive Myasthenia Gravis

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular...

CPRX : 5.31 (+0.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade CPRX with:

Business Summary

CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for...

See More

Key Turning Points

2nd Resistance Point 5.49
1st Resistance Point 5.40
Last Price 5.31
1st Support Level 5.16
2nd Support Level 5.01

See More

52-Week High 5.68
Last Price 5.31
Fibonacci 61.8% 4.22
Fibonacci 50% 3.76
Fibonacci 38.2% 3.31
52-Week Low 1.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar